[Adjuvant chemotherapy for colorectal carcinoma after curative resection].
Murakami
Masakazu
M
Department of Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine and Dentistry.
Tsukuda
Kazunori
K
Ota
Tetsuya
T
Naito
Minoru
M
Shimizu
Nobuyoshi
N
D000284:Administration, Oral; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine; D017024:Chemotherapy, Adjuvant / Q000639:trends; D002986:Clinical Trials as Topic; D003082:Colectomy; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000601:surgery*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000235:genetics; D019317:Evidence-Based Medicine; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D007978:Levamisole / Q000008:administration & dosage; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D011379:Prognosis
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D007978:Levamisole; D000069287:Capecitabine; D042943:Dihydrouracil Dehydrogenase (NADP); D002955:Leucovorin; D005472:Fluorouracil